A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Jul 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Dec 2020 New trial record